BRAF and acute myeloid leukemia: As illustrated in Figure 4, the AML patients with BRAF mutations showed an extremely poor prognosis (n = 7) compared to that of the de novo AML patients or secondary AML patients without BRAF mutations, with a median survival time of 126 days, ranging from 2 to 290 days (p = 0.0012).